• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements

    2/26/25 7:00:00 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EYEN alert in real time by email

    NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announced that it has been informed by staff of The Nasdaq Stock Market LLC that the Company has regained compliance with all Nasdaq Capital Market continued listing requirements, including Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement rule, and Listing Rule 5810(c)(3)(A)(iii), the low priced stocks rule.

    "Maintaining our Nasdaq listing, along with other steps we have taken to restructure the company and accelerate development of the user-filled Optejet, represent important milestones as we continue to evaluate a broad range of strategic alternatives and maximize shareholder value," stated Michael Rowe, Chief Executive Officer. "We are grateful to our shareholders who approved of our recent decision to effect a reverse stock split that made it possible for us to regain compliance with the Nasdaq continued listing requirements."

    About Eyenovia, Inc.

    Eyenovia, Inc. is an ophthalmic technology company developing its proprietary Optejet topical ophthalmic medication dispensing platform. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may combine to produce better treatment options and outcomes for patients and providers. For more information, please visit Eyenovia.com.

    Forward Looking Statements

    Except for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including those relating to the estimated market opportunities for our platform technology, the timing for sales growth of our approved products, and the outcome of the process to explore strategic alternatives to maximize shareholder value. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission.

    In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the potential advantages of our products, and platform technology; the rate and degree of market acceptance and clinical utility of our products; our estimates regarding the potential market opportunity for our products; reliance on third parties to develop and commercialize our products; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our products; intellectual property risks; changes in legal, regulatory, legislative and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products and product candidates; our competitive position; and our ability to raise additional funds and to make payments on our debt obligations as and when necessary.

    Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.

    Eyenovia Contact:

    Eyenovia, Inc.

    Norbert Lowe

    Vice President, Commercial Operations

    [email protected]

    Eyenovia Investor Contact:

    Eric Ribner

    LifeSci Advisors, LLC

    [email protected]

    (646) 751-4363



    Primary Logo

    Get the next $EYEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EYEN

    DatePrice TargetRatingAnalyst
    11/18/2024$12.00 → $2.00Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $EYEN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for MYDCOMBI issued to EYENOVIA INC.

      Submission status for EYENOVIA INC.'s drug MYDCOMBI (ORIG-1) with active ingredient TROPICAMIDE AND PHENYLEPHRINE HYDROCHLORIDE has changed to 'Approval' on 05/05/2023. Application Category: NDA, Application Number: 215352, Application Classification: Type 5 - New Formulation or New Manufacturer

      5/8/23 1:05:04 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EYEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Eyenovia Announces Co-Branded Validator with Kinetiq

      LAGUNA HILLS, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced a co-branded Hyperliquid validator with Kinetiq, a leading liquid staking protocol built natively for the Hyperliquid ecosystem.  The validator marks a significant step in Eyenovia's onchain engagement strategy, utilizing its recent acquisition of 1,040,584.5 HYPE to contribute directly to network stability and security. Validator operations are further supported by infrastructure provided by Pier

      6/25/25 8:30:00 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia Announces Closing of $50 Million Private Placement, Successful Accumulation of More Than One Million HYPE Tokens, and Update on its Optejet Development Program

      The significant HYPE token position, acquired at an average price of approximately $34 per token, makes Eyenovia the first Nasdaq listed company to run a validator on Hyperliquid FDA registration of the Optejet User Filled Device (UFD) on track for September 2025; meaningful partnering discussions ongoing LAGUNA HILLS, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced the closing of its previously announced $50 million private placement (PIPE) with ac

      6/23/25 8:30:00 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Expands into Digital Assets by Advising Strategic Crypto-Backed Financings

      NEW YORK, June 18, 2025 /PRNewswire/ -- Chardan, a leading global investment banking and advisory firm, today announced an expansion into the digital asset sector, advising on and structuring a series of transactions that bridge traditional capital markets with the rapidly evolving world of blockchain and cryptocurrency. As part of its strategic push into crypto finance, Chardan has recently served as a strategic advisor and placement agent in the following notable transactions: Eyenovia's $50 Million PIPE to Acquire HYPE Tokens Chardan acted as sole placement agent in Eyenovi

      6/18/25 2:04:00 PM ET
      $EYEN
      $KIDZ
      $LGHL
      $VVPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Other Consumer Services
      Real Estate

    $EYEN
    SEC Filings

    See more
    • Eyenovia Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - EYENOVIA, INC. (0001682639) (Filer)

      6/24/25 4:05:59 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eyenovia Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - EYENOVIA, INC. (0001682639) (Filer)

      6/5/25 8:00:19 AM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Eyenovia Inc.

      424B5 - EYENOVIA, INC. (0001682639) (Filer)

      6/2/25 4:01:05 PM ET
      $EYEN
      Biotechnology: Pharmaceutical Preparations
      Health Care